drugset / Trial / NCT03018249

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

NCT03018249

RandomizedParallel-groupOpen-labelBasic science

Summary

This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving medroxyprogesterone acetate with or without entinostat may effect tumors from endometrioid endometrial cancer.

Timeline

Start
2017-10-11
Primary completion
2018-04-18
Completion
2021-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule Oral
Background medroxyprogesterone acetate Other / unclassified Intramuscular